Robert Panza
Westfield, NJNPI 1013074434
Payments from drug & device makers
$3,577in general payments, 2019–2025
Across 117 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Corium, LLC$291
- GSK$197
- Takeda Pharmaceuticals U.S.A., Inc.$179
- Merck$138
- Sanofi Pasteur Inc.$120
- plus $527 from 13 others
What the payments were for
- Speaking & faculty fees$1,92554%
- Food & beverage$1,65246%
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $2,125 |
| Corium, LLC | 20 | $291 |
| GSK | 12 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $179 |
| Merck | 10 | $138 |
| Sanofi Pasteur Inc. | 8 | $120 |
| Cranial Technologies, Inc | 8 | $110 |
| Tris Pharma Inc | 6 | $82 |
| Alk-abello, Inc | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Supernus Pharmaceuticals, Inc. | 3 | $39 |
| Adlon Therapeutics L.p. | 3 | $39 |
| Genentech USA, Inc. | 3 | $38 |
| Organon | 2 | $31 |
| Aytu Biopharma, Inc. | 2 | $31 |
| Vivus LLC | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| Dermira, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRUMENBA$1,925
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.